Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07690579 · ClinicalTrials.gov registry record

Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities

A clinical trial, sponsored by University of California, San Francisco.

Recruiting
Registry status
350
Enrollment target

NCT07690579: Recruiting study, sponsored by University of California, San Francisco.

NCT07690579 is a clinical trial that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 350 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07690579 is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
350 participants
Enrollment target

Study Summary

Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proportion alike of cancer diagnoses and deaths. In the prostate specific antigen (PSA)-based screening era, mortality rates improved at a similar velocity among Black and White men, but the 2- to 3-fold excess mortality burden borne by Black men has persisted over the past 40 years, the second highest among all major cancers. In recent years mortality is rising among Black men, and at a rapid velocity. The explanations for this disparity-the extent to which it is attributable to genetics, environmental factors including Structural and Social Determinants of Health (SSDH), or access to care-are multifactorial and have been elucidated to a limited extent. A large meta-analysis recently found that across dozens of studies and cohorts, greater adjustment for clinical and SSDH factors generally resulted in race itself dropping as a significant predictor. These and other findings suggest that the determinants of disparity be identified at time of, and prior to, cancer diagnosis, and that both genetic and environmental factors contribute to earlier development and progression.

Primary Outcome

Genomic and SSDH factors will be evaluated to locate not yet identified factors that are associated with greater immune activation and prediction of unfavorable vs. favorable prostate cancer biology by race and ethnicity groups.

Interventions

  • OTHER Questionnaires
  • OTHER Medical Record Review

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2026-03-31
Est. Completion 2028-03-31

What NCT07690579 shows while recruiting

NCT07690579 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 2 interventions - of which Questionnaires is the first listed.

NCT07690579 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07690579 about?

NCT07690579 is a clinical study titled "Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities". Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proportion alike of cancer diagnoses and deaths. In the prostate specific antigen (PSA)-based screening era...

What is the current status of trial NCT07690579?

This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2026-03-31. Estimated completion is 2028-03-31.

What interventions are being tested in trial NCT07690579?

The interventions under investigation include: Questionnaires (OTHER), Medical Record Review (OTHER).

Who is sponsoring clinical trial NCT07690579?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900575 · 350 participants · NA

    Cervical Cancer Detection Using Optical Spectroscopy

  • NCT01627821 · 350 participants · NA

    Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study

  • NCT02357654 · 350 participants · Phase 4

    GnRH for Luteal Support in IVF/ICSI/FET Cycles

  • NCT03997370 · 350 participants · Phase 1

    Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07690579, the US trial registry maintained by the National Library of Medicine. NCT07690579 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.